Research Update CHF 02534 EY 3 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma

We opened the trial on July 1, 2019. As of June 27, 2021, we have enrolled 18 dogs in the study and no dose limiting toxicities within the initial 21-day assessment period have been observed. Based on these results, we are continuing to enroll dogs at the highest dose of propranolol (1.3 mg/kg) being tested.

Propranolol and doxorubicin levels in the blood from all of the dogs enrolled to date have been analyzed.

Currently, five dogs enrolled in the study are alive while thirteen dogs have succumbed to their disease. Two of the dogs have survived for more than two years. These dogs have graduated from the study, but we are continuing to monitor their progress. Three other dogs are alive, and one of these dogs will reach the 1-year survival milestone in approximately 12 weeks. The other two dogs are approaching their 9-month and 6-month milestones. We are excited about the potential for a third dog reaching the one-year milestone, and we are optimistic regarding the other two dogs who continue to do well.

We have completed the analysis of drug levels (propranolol and doxorubicin) in the blood samples.

Due to delays related to the pandemic, we requested an extension of the study in order to provide a complete follow-up (up to one year) for all of the dogs enrolled.

End-Year 3 Research Update Dr. Dickerson for improved response to chemotherapy treatment in hemangiosarcoma.